Carlos Luis Lopez
Known title: SVP, General CounselCIK: 0002042509
Carlos Luis Lopez's purchase track record
Carlos Luis Lopez has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/7/2025 | NAGE | $2K | +68.2% | +22.2% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NAGE | ▲ Buy | Grant | 2,314 | $6K | 6/30/2026 | View on chart |
| NAGE | ▲ Buy | Open Market | 273 | $2K | 3/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
NAGE linked to new preclinical study on CD38 and NAD+ decline
A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.
NAGE linked to new preclinical study on CD38 and NAD+ decline. A new preclinical study identified CD38 as a driver of age‑related NAD+ decline and showed that nicotinamide riboside can improve pregnancy outcomes in animal models. The research also reported lower NAD+ levels in placental tissue from older mothers. Niagen Bioscience clarified that it did not conduct, fund, or design the study and that the NR used was not its proprietary Niagen ingredient. The findings relate to the company’s focus on NAD+‑boosting products and may draw attention to its pipeline.